TransFix® was developed by medical scientists from UK NEQAS, which is part of Sheffield Teaching Hospitals NHS Foundation Trust. TransFix® was developed out of the requirement to produce stabilised blood samples that could be used in External Quality Assurance programs for flow cytometry. The first publication on TransFix® as a cellular antigen stabilizing reagent was made in 1999 by D. Barnett et al.
TransFix® has been in circulation in the research world from 1999 until the present day, generating a number of scientific publications. In 2005 the Sheffield Teaching Hospitals NHS Foundation Trust licensed TransFix® to Cytomark in order to make it more generally available to the clinical and scientific world.
Cytomark is a Division of Caltag Medsystems Ltd.
Caltag Medsystems Ltd. is registered in the UK, No. 4162330
Registered Office: 69 Little London, Towcester, NN12 8UP
VAT Reg. No. GB 765 6661 89